This article is more than 5 years old. Information may no longer be current.

Encore Vision completes enrollment for phase 1/2 trial of EV06 for presbyopia

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Encore Vision has completed patient enrollment for a phase 1/2 trial of topical EV06 ophthalmic solution for the treatment of presbyopia, according to a press release.

The prospective, randomized, double-masked, multicenter trial will examine the safety and efficacy of EV06 (lipoic acid choline ester 1.5%) compared with placebo for 90 days to treat presbyopia.

The trial includes 75 patients with distance corrected near visual acuity worse than 20/40 and best corrected distance visual acuity of 20/20 or better in each eye.

Researchers will evaluate mean change in distance corrected near visual acuity and best corrected distance visual acuity, as well as additional secondary outcomes, the release said.

“We are pleased to confirm that 75 subjects have been enrolled in the study, and to date, there have been no safety or tolerability issues,” Bill Burns, president and CEO of Encore, said in the release.

The company expects to announce topline results in the second quarter.